FDA issues 17 observations for Lupin’s manufacturing facility

Oct 19, 2022

Lupin disclosed that the FDA has issued 17 observations in relation to its biotech manufacturing facility in Pune, India.  Lupin announced that it is committed to addressing the concerns raised by the FDA, and that it does not expect the observations to impact on the existing revenues raised through this facility.

Print Page Mail Article